HST Global, Inc. is a Hampton, Virginia based development-stage biotechnology company focused on the acquisition, development and commercialization of innovative products to enhance cancer care. We endeavor to obtain proprietary rights to these products, by in-licensing or otherwise, fund their research and development and bring the products to market. Since our inception in 2008, our efforts and resources have been focused primarily on Salicinium, our clinical stage drug candidate, raising capital and recruiting personnel.

We focus on in-licensing and further developing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer. Although the cost of licensing drug candidates for which the initial clinical testing has been completed may be significantly higher than those for which clinical testing has not been completed, we believe there is significantly less risk associated with our investment and continued development of clinical stage drugs due to the fact that we are able to obtain an initial indication of the drug’s safety and efficacy before we decide to invest our capital in the drug’s development.

Our core concept remains unique in clinical drug development. Despite numerous other pharmaceutical and biotech companies worldwide, HST is one of the few companies working to create relationships and partnerships for the development of prescription drugs from natural sources to address current and emerging health crises.

At HST Global, we have a holistic perspective and believe that the synergy amongst the parts of a plant or substances from other natural sources have significant value. We believe that these synergies are perhaps one reason for the positive outcomes we encounter in our pre-clinical and clinical investigations. We take this approach because we believe that plant co-factors, instead of a single chemical entity, will increase the overall safety and efficacy of the medicines we eventually produce.